NCT04187560View on ClinicalTrials.gov

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 22, 2020

Primary Completion Date

July 1, 2020

Study Completion Date

November 9, 2020

Conditions
Schizophrenia
Interventions
DRUG

LB-102

(N-Methyl amisulpride)

Trial Locations (1)

45227

Medpace Clinical Pharmacology LLC, Cincinnati

Sponsors
All Listed Sponsors
lead

LB Pharmaceuticals Inc.

INDUSTRY